We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
Topics Covered
- RARs (NR1B1-3)
- Vitamin A
- Roles or RAR
- RAR mechanisms in cancer
- Therapeutic indications for RAR modulators
- RAR modulator drugs
- RAR as a male contraceptive
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Merk, D. (2025, July 31). Retinoic acid receptors (NR1B) - biological role & drugs [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved August 2, 2025, from https://doi.org/10.69645/AFCA8498.Export Citation (RIS)
Publication History
- Published on July 31, 2025
Financial Disclosures
- Daniel Merk discloses affiliations with Ludwig-Maximilians-University Munich and the Free State of Bavaria. He is a member of the German Pharmaceutical Society (DPhG) and the German Chemical Society (GDCh). He has received honoraria for lectures, authoring, reviewing, and advisory activities from the DPhG, German Associations of Pharmacists, German Medical Association, Sanofi, Boehringer Ingelheim, ONO Pharmaceuticals, YS Life Science, AVOXA, SpringerNature, Wiley, and the Swiss National Science Foundation (SNF). Additionally, he holds five patents or patent applications related to nuclear receptor modulators and other small molecule drugs. His research is funded by the European Research Council (ERC), Innovative Medicines Initiative (IMI), German Research Foundation (DFG), German Federal Agency for Disruptive Innovation (SPRIN-D), and Immunic AG.
Other Talks in the Series: Nuclear Receptors as Common Therapeutic Targets
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome, everyone,
to Chapter 10 of this
short talk series on
nuclear receptors as
therapeutic targets.
0:10
This chapter will address
the retinoic acid receptors,
which exist in three subtypes,
RAR-alpha, beta, and gamma,
and represent the NR1B family.
0:22
The retinoic acid receptors are
closely linked to vitamin A
and bind the vitamin A metabolite
all-trans retinoic acid
as a natural ligand.
For this, the provitamin
beta-carotene
is oxidatively
cleaved to retinal,
which is essential for
vision and other processes.
Retinal is further
oxidized to retinoic acid,
which exists in a
number of isomers.
The all-trans retinoic acid,
often abbreviated as ATRA,
is the natural agonist of
retinoic acid receptors,
while the 9-cis retinoic acid,
and, likely also,
other related species,
are natural retinoid
X receptor ligands.
As RAR typically acts as
a heterodimer with RXR,
also the 9-cis retinoic acid
and related metabolites
are relevant to RAR activity.
1:14
The RAR-RXR heterodimer
is DNA-bound also
in the absence of a ligand,
recruits corepressors,
and thus can act as a
transcriptional repressor.
Agonist binding,
for example all-trans
retinoic acid,
leads to corepressor release
and coactivator recruitment
to enable transcription.
With both the repressor
and transcriptional
activator activity,
RAR involves in many
physiological processes.
RAR activity is essential
for development of many organs
and also has a role in
regulating cell differentiation
and apoptosis.
RAR activation can induce
terminal differentiation
of certain cancer cells,
and there are mutant
RAR forms that act as
overactive repressors
in some cancers.
RAR agonism, thus, has
potential in cancer treatment.
Additionally, RAR
participates in
the transcriptional regulation
of cancer resistance factors,
like drug transporters,
and RAR is also involved
in the regulation
of hematopoietic stem
cells and immune cells.
Lastly, it has an
important role in the skin
by controlling keratinocyte
proliferation,
epidermal cell turnover,
and collagen production.